BackKezar Life Sciences Overview

Kezar Life Sciences Other Current Liabilities

Latest other current liabilities for KZR: $1.1M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.14M
72.64% YoYΔ $-3.01M vs prior year quarter

Peer trimmed avg / median

Loading

Kezar Life Sciences Other Current Liabilities History

Loading

Kezar Life Sciences vs. peers: Other Current Liabilities Comparison

Loading

Kezar Life Sciences Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kezar Life Sciences (KZR) FAQ

As of the most recent data (March 2026), KZR shows a other current liabilities of $1.1M. That compares with $4.1M in the prior-year period — down 72.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KZR's other current liabilities is now $1.1M (was $4.1M) — a 72.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kezar Life Sciences is outperforming or lagging.

Tracking KZR's other current liabilities over time shows whether Kezar Life Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $1.1M That compares with $4.1M in the prior-year period — down 72.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Kezar Life Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.1M) with ownership activity and broader fundamentals.

Kezar Life Sciences's other current liabilities is $1.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.